There are 2185 resources available
850MO - Phase II randomized trial of chemotherapy followed by surgery and PORT versus surgery and PORT for organ preservation of T3 and T4a (selected T4b) sinonasal squamous cell carcinoma (SNC): A trial of the ECOG-ACRIN cancer research group (EA3163)
Presenter: Nabil Saba
Session: Mini oral session: Head and neck cancer
Resources:
Abstract
LBA53 - Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: Results from the randomized phase II RELATIVITY-104 study
Presenter: Nicolas Girard
Session: Proffered paper session: NSCLC metastatic
Resources:
Abstract
LBA59 - Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Final results of the IKF-AIO-Moonlight trial
Presenter: Sylvie Lorenzen
Session: Proffered paper session 2: GI tumours, upper digestive
Resources:
Abstract
867MO - Epigenetic therapy modulates the tumor microenvironment to sensitize anti-PD-1 refractory head and neck cancers to immunotherapy
Presenter: Austin Mattox
Session: Mini oral session: Head and neck cancer
Resources:
Abstract
851MO - Final analysis of a phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of the head and neck (JCOG1008)
Presenter: Makoto Tahara
Session: Mini oral session: Head and neck cancer
Resources:
Abstract
LBA54 - Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2
Presenter: Sanjay Popat
Session: Proffered paper session: NSCLC metastatic
Resources:
Abstract
1400O - Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma
Presenter: Sara Lonardi
Session: Proffered paper session 2: GI tumours, upper digestive
Resources:
Abstract
LBA37 - Final results: Randomized assessment of cisplatin dosing interval for ototoxicity (RADIO) trial comparing chemoradiation (CRT) with cisplatin q3weekly to weekly for locally advanced squamous cell carcinoma of the head and neck (LASCCHN)
Presenter: M. Kuruvilla
Session: Mini oral session: Head and neck cancer
Resources:
Abstract
LBA55 - Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study
Presenter: Benjamin Besse
Session: Proffered paper session: NSCLC metastatic
Resources:
Abstract
1401O - Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)
Presenter: Yelena Janjigian
Session: Proffered paper session 2: GI tumours, upper digestive
Resources:
Abstract